BamSEC and AlphaSense Join Forces
Learn More

Sarepta Therapeutics Inc.

NASDAQ: SRPT    
Share price (12/20/24): $118.97    
Market cap (12/20/24): $11.4 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 4 pages By Email September 16, 2024 Jpmorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5jp England Re: Supplement to Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation to Whom It May Concern
12/34/56
EX-10.1
from 10-Q 4 pages By Email September 16, 2024 Goldman Sachs & Co. LLC 200 West Street New York, Ny 10282-2198 Attention: Josh Murray, Equity Capital Markets Telephone No.: [**] Re: Supplement to Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation to Whom It May Concern
12/34/56
EX-10.1
from 8-K 1 page Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan
12/34/56
EX-10.3
from 10-Q 7 pages Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.2
from 10-Q 8 pages Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Stock Option Award Agreement
12/34/56
EX-10.77
from 10-K 5 pages Sarepta Therapeutics, Inc. Policy for Recoupment of Incentive Compensation
12/34/56
EX-10.74
from 10-K 6 pages Fourteenth Amendment to License, Collaboration, and Option Agreement This Fourteenth Amendment to License, Collaboration, and Option
12/34/56
EX-10.73
from 10-K 6 pages Thirteenth Amendment to License, Collaboration, and Option Agreement This Thirteenth Amendment to License, Collaboration, and Option Agreement
12/34/56
EX-10.72
from 10-K 6 pages Twelfth Amendment to License, Collaboration, and Option Agreement This Twelfth Amendment to License, Collaboration, and Option Agreement
12/34/56
EX-10.71
from 10-K 6 pages Eleventh Amendment to License, Collaboration, and Option Agreement This Eleventh Amendment to License, Collaboration, and Option Agreement
12/34/56
EX-10.5
from 10-Q 3 pages First Amendment to the Amended and Restated Lead Dmd Product Manufacturing & Supply Agreement 1
12/34/56
EX-10.4
from 10-Q 4 pages Second Amendment to Exclusive License Agreement Between the Research Institute at Nationwide Children’s Hospital and Sarepta Therapeutics Three LLC
12/34/56
EX-10.3
from 10-Q 4 pages [**] = Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Information That the Company Customarily and Actually Treats as Private or Confidential and (II) Is Not Material
12/34/56
EX-10.2
from 10-Q 42 pages [**] = Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Information That the Company Customarily and Actually Treats as Private or Confidential and (II) Is Not Material
12/34/56
EX-10.1
from 10-Q 81 pages [**] = Identified Information Has Been Excluded From This Exhibit Because It Is Both (I) Information That the Company Customarily and Actually Treats as Private or Confidential and (II) Is Not Material Amended & Restated Lead Dmd Product Manufacturing & Supply Agreement by and Between Sarepta Therapeutics Three, LLC and Catalent Maryland, Inc. Dated as of November 28, 2022
12/34/56
EX-10.2
from 8-K 2 pages Amendment No. 2 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 2 pages Amendment No. 3 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 16 pages Exchange Agreement
12/34/56
EX-10
from 10-K 20 pages Separation and Consulting Agreement and General Release
12/34/56
EX-10
from 10-K 3 pages November 18, 2022 Mr. Douglas S. Ingram Re: Amendments to Employment Agreement Sarepta Therapeutics, Inc. By: /S/ Ryan Brown Name: Ryan E. Brown Title: Svp, General Counsel Accepted and Agreed: /S/ Douglas S. Ingram Name: Douglas S. Ingram Date: November 18, 2022
12/34/56